LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.54 +0.01 (+2.67%) As of 12:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ValiRx Stock (LON:VAL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ValiRx alerts:Sign Up Key Stats Today's Range 0.50▼ 0.5550-Day Range 0.50▼ 0.8052-Week Range 0.38▼ 2.37Volume790,048 shsAverage Volume4.80 million shsMarket Capitalization£2.02 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company Overview ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development. Read More Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAL Stock News HeadlinesEARNINGS: ValiRx says trading "challenging"; Mindflair swings to lossSeptember 29, 2025 | lse.co.ukValiRx’s Cytolytix Advances Cancer Therapeutics with Key Patent and Platform DevelopmentsSeptember 1, 2025 | tipranks.comThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It exposes an unstoppable economic force that could devastate millions of Americans financially while creating massive new wealth for others. Goldman Sachs estimates more than 12,000 people a day are already being affected. You deserve to see what’s really happening before it accelerates.October 16 at 2:00 AM | Porter & Company (Ad)ValiRx establishes new subsidiary for prostate cancer assetsAugust 26, 2025 | lse.co.ukValiRx Expands Prostate Cancer Portfolio with New SubsidiaryAugust 26, 2025 | tipranks.comValiRx Updates Evaluation Agreement with Stingray Bio for Cancer TherapeuticsAugust 5, 2025 | tipranks.comValiRx subsidiary Inaphaea agrees exclusive PredictRx licensing dealAugust 4, 2025 | lse.co.ukValiRx Partners with VoxCell for Advanced Cancer Model DevelopmentJuly 29, 2025 | tipranks.comSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.65 on January 1st, 2025. Since then, VAL stock has decreased by 17.1% and is now trading at GBX 0.54. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its earnings results on Monday, September, 29th. The company reported ($0.22) earnings per share (EPS) for the quarter. ValiRx had a negative net margin of 20,554.01% and a negative trailing twelve-month return on equity of 55.84%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO). Company Calendar Last Earnings9/29/2025Today10/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPetroleum And Natural Gas Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-20,554.01% Pretax MarginN/A Return on Equity-55.84% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.44 Current Ratio6.65 Quick Ratio1.27 Sales & Book Value Annual Sales£49.78 thousand Price / Sales37.75 Cash FlowGBX 0.01 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.19Miscellaneous Outstanding Shares374,349,000Free FloatN/AMarket Cap£1.88 million OptionableNot Optionable Beta0.59 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (LON:VAL) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
